Chimerix, Inc. (NASDAQ:CMRX) Shares Sold by Armistice Capital LLC

Armistice Capital LLC lowered its position in shares of Chimerix, Inc. (NASDAQ:CMRX) by 1.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,224,000 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Armistice Capital LLC owned about 2.48% of Chimerix worth $1,948,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Koshinski Asset Management Inc. purchased a new position in Chimerix during the 1st quarter worth approximately $42,000. Marquette Asset Management LLC grew its position in shares of Chimerix by 24.3% during the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 22,709 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter valued at $137,000. Pale Fire Capital SE raised its position in Chimerix by 113.6% in the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 112,318 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Chimerix in the 4th quarter valued at $1,348,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Stock Performance

Shares of Chimerix stock opened at $0.90 on Friday. Chimerix, Inc. has a one year low of $0.75 and a one year high of $1.30. The company has a market cap of $80.98 million, a P/E ratio of -0.97 and a beta of 1.12. The firm has a fifty day moving average of $0.90 and a two-hundred day moving average of $0.93.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period in the prior year, the company posted ($0.21) earnings per share. As a group, equities analysts predict that Chimerix, Inc. will post -0.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on CMRX shares. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, August 14th.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.